BioFirst obtains patent protection for “Ophthalmic Surgical Fluid” in Canada right after Australia (August 07,2014

BioFirst (6458) Corp has good news again, after receiving patent protection for its “ Artificial Vitreous” technology in the US, Taiwan, Australia, Korea; today (August o6), BioFirst receives patent protection in Canada for another core product: “Ophthalmic Surgical Fluid”, this product has patent in two countries now including the patent in Australia granted previously.
According to the statistic repot from National Health Insurance Administration, there are about 150,000 Ophthalmic surgeries conducted every year in Taiwan, and there were about 100,000 patients underwent cataract operations, the Health Insurance expenditure is estimated to reach NT$2-3 Billion with enormous global market. During the ophthalmic operations, it is essential to use specific formulated fluid to accelerate the recovery from surgery, and there is only one product available currently. BioFirst’s newly invented ”Ophthalmic Surgical Fluid” obtained exclusive authorization from the NHRI (National Health Research Institution) for global market, it can be used in various Ophthalmic operations, and the unique formula can enhance the protection of ophthalmic tissues, accelerate the recovery, and can reduce the risk of corneal edema and contraction. This fluid will not affect patient’s vision even with residue after surgery.
"Opthalmic Surgical Fluid” is classified as new drug, this unique new formula has potential to proceed with Phase III clinical trial directly, which can significantly reduce the time from development to launch. BioFirst has submitted patent protection application to over 10 countries including Taiwan, US etc… with complete global patent coverage.